11/ 2010. The Royal Academy of Pharmacy

The journal Clinical and Experimental Immunology publishes an interesting study with BACTEK administered through the sublingual route. Both the specific response to the antigens contained in the vaccine and the clinical outcome of vaccinated patients with recurrent respiratory infections are assessed.

This study, performed by the Hospital General Universitario Gregorio Marañón, Madrid, shows the immunological and clinical improvement after vaccination. BACTEK is a polyvalent bacterial vaccine manufactured by Inmunotek.

Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome.

D. Alecsandru, L. Valor, S. Sánchez-Ramón, J. Gil, J. Carbone, J. Navarro, J. J. Rodríguez, C. Rodríguez-Sainz and E. Fernández-Cruz

Clinical Immunology Unit, Immunology, Department, Hospital General Universitario Gregorio Marañón, Departamento de Microbiología I, Universidad Complutense de Madrid, Spain.

+ info

02/2011. Estudio BACTEK

GuardarGuardar

GuardarGuardar